1. Phylogeny  
NTRK2, widely known as TrkB, is a member of the neurotrophin receptor tyrosine kinase family that also includes TrkA (NTRK1) and TrkC (NTRK3). These proteins exhibit a high degree of conservation across vertebrate species, being detected in mammals, birds, amphibians, and fish. Gene duplication events in early vertebrate evolution gave rise to this family, and the shared domain architecture among the Trk receptors reinforces their common origin. In particular, comparative studies have demonstrated that the conserved extracellular domains and intracellular kinase domains in TrkB reflect an evolutionary core that is essential for proper neurotrophic signaling. This evolutionary lineage situates TrkB alongside other receptor tyrosine kinases that have similar regulatory and functional roles in nervous system development and maintenance (benitogutierrez2006originandevolution pages 2-3, benitogutierrez2006originandevolution pages 7-8, yan2018insightsintocurrent pages 1-3, ambjørn2013alossoffunctionscreen pages 1-2).

2. Reaction Catalyzed  
TrkB catalyzes an ATP-dependent phosphorylation reaction whereby a phosphate group is transferred from ATP to specific tyrosine residues on substrate proteins. The catalytic reaction can be succinctly expressed as:  
  ATP + [protein]-tyrosine → ADP + [protein]-phosphotyrosine + H⁺  
This reaction is initiated upon ligand-induced receptor dimerization, which leads to autophosphorylation of the intracellular kinase domain and subsequent phosphorylation of downstream substrates (amatu2019tropomyosinreceptorkinase pages 1-2, thiriet2013preambletocytoplasmic pages 1-4, fabbro2015tenthingsyou pages 1-2).

3. Cofactor Requirements  
The kinase activity of TrkB is dependent on the presence of ATP as the phosphate donor and requires divalent cations—most notably Mg²⁺—to facilitate proper binding and orientation of the ATP molecule within the active site. The Mg²⁺ cofactor plays a critical role in stabilizing the transition state during phosphoryl transfer, thus ensuring the efficiency of the catalytic process (fabbro2015tenthingsyou pages 1-2, thiriet2013preambletocytoplasmic pages 1-4).

4. Substrate Specificity  
TrkB exhibits substrate specificity typical of receptor tyrosine kinases. Upon ligand stimulation, the receptor undergoes dimerization and autophosphorylation of key tyrosine residues situated within the activation loop and flanking regions. These phosphorylated tyrosine sites function as docking motifs for adaptor proteins containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains. For instance, the phosphorylation events occurring at sites such as Y705 in the activation loop and additional residues like Y496 and Y791 facilitate the recruitment of downstream signaling molecules including SHC1, FRS2, SH2B1, SH2B2, and PLCG1. Although a singular consensus substrate motif for TrkB has not been comprehensively defined, the receptor’s kinase domain is known to preferentially phosphorylate tyrosine residues when presented within a conformational context that supports adaptor binding. This substrate recognition underpins the activation of key signaling cascades such as the Ras-MAPK, PI3K-AKT, and PLCγ pathways (amatu2019tropomyosinreceptorkinase pages 1-2, gupta2013trkbreceptorsignalling pages 11-13, gupta2020constitutivelyactivetrkb pages 8-10, yan2018insightsintocurrent pages 29-30).

5. Structure  
TrkB is organized as a single-pass transmembrane receptor that comprises several distinct functional domains. Its extracellular region begins with an N-terminal signal peptide followed by a complex ligand‐binding domain that includes two cysteine-rich clusters, a series of three leucine-rich repeats, and two immunoglobulin-like (Ig) domains (Ig1 and Ig2). These extracellular motifs are critical for high-affinity interaction with its primary ligand, brain-derived neurotrophic factor (BDNF), as well as neurotrophin-4 (NT4), while also accommodating binding to neurotrophin-3 (NT3) with reduced efficacy (amatu2019tropomyosinreceptorkinase pages 1-2, benitogutierrez2006originandevolution pages 2-3, yan2018insightsintocurrent pages 29-30).

The receptor then spans the plasma membrane via a single transmembrane helix that ensures the proper anchoring of the receptor in the lipid bilayer. Positioned immediately downstream of the transmembrane segment is the intracellular region, which is dedicated to signal transduction. Central to this region is the tyrosine kinase domain—a catalytic module that contains key structural motifs such as the ATP-binding pocket, the catalytic loop, the activation loop, the DFG motif, and a conserved C-helix. Notably, structural studies, including high-resolution crystallographic analyses, have elucidated details of the kinase domain, such as the essential role of a conserved lysine residue within the ATP-binding site (gupta2020constitutivelyactivetrkb pages 49-53, bertrand2012thecrystalstructures pages 1-2).  
In addition to these conserved motifs, the intracellular region of the full-length receptor harbors several autophosphorylation sites—five critical tyrosine residues are typically highlighted, with three residing in the activation loop and two located proximally outside the kinase domain that serve as docking sites for effector proteins. Alternative splicing events give rise to isoform diversity; truncated isoforms like TrkB-T1 retain the extracellular and transmembrane regions while lacking the intracellular kinase domain, thereby modulating signaling output possibly through dominant-negative mechanisms or alternative effector recruitment (gupta2013trkbreceptorsignalling pages 4-6, wessels2014thebrainuterusconnection pages 10-10, gupta2020constitutivelyactivetrkb pages 8-10).  
Furthermore, structural elucidation by crystallography has revealed unique features of the kinase domain, such as variations in the kinase insert domain (KID), which may contribute to subtle differences in conformational dynamics and inhibitor selectivity when compared with other Trk family members (bertrand2012thecrystalstructures pages 10-11, gupta2020constitutivelyactivetrkb pages 49-53). These modular domains work coordinately to ensure that TrkB not only binds its ligands with high specificity but also initiates a robust signaling response upon activation.

6. Regulation  
TrkB regulation is a multi-tiered process that involves ligand-induced receptor dimerization, subsequent autophosphorylation, and additional post-translational modifications that fine-tune signal propagation. Upon binding of its cognate ligands (BDNF or NT4), TrkB undergoes conformational changes that promote homodimerization. This receptor dimerization facilitates trans-autophosphorylation of critical tyrosine residues within the intracellular kinase domain, which, in turn, generates binding sites for downstream adaptor proteins and initiates intracellular signaling cascades (amatu2019tropomyosinreceptorkinase pages 1-2, gupta2013trkbreceptorsignalling pages 1-4).

Key regulatory phosphorylation events, particularly at residues within the activation loop (for example, Y705) and additional sites such as Y496 and Y791, are essential for full enzymatic activation and for recruiting proteins that contain SH2 or PTB domains. These phosphorylation events serve as molecular switches that propagate the signal through pathways such as the Ras-MAPK and PI3K-AKT cascades (cocco2018ntrkfusionpositivecancers pages 3-4, gupta2020constitutivelyactivetrkb pages 43-49).  
In addition to ligand-dependent activation, TrkB may also be subject to ligand-independent regulatory mechanisms. Constitutive activation has been observed in certain pathological contexts, where overexpression or aberrant intracellular domain activity leads to persistent kinase activity. Such constitutive signaling is frequently observed in cancerous cells, including glioblastomas, and contributes to oncogenic phenotypes (gupta2020constitutivelyactivetrkb pages 1-5, gupta2020constitutivelyactivetrkb pages 13-16).  
Another layer of TrkB regulation is provided by ubiquitination. Studies have demonstrated that specific lysine residues in the intracellular domain, such as K811 (or its analogous position in some analyses), are targets for K63-linked polyubiquitination mediated by E3 ubiquitin ligase complexes involving TRAF6 and the adaptor protein p62. This ubiquitin modification modulates receptor stability and signaling by altering receptor turnover and potentially influencing downstream pathway activation (singh2018traf4mediatedubiquitinationof pages 15-15).  
Alternative splicing further contributes to the regulatory complexity of TrkB by generating isoforms with different intracellular compositions. For example, the truncated isoform TrkB-T1, which lacks the catalytic domain, is predominant in certain cell types such as astrocytes and has been implicated in the modulation of intracellular calcium dynamics, adding yet another level of control over neurotrophin signaling (gupta2013trkbreceptorsignalling pages 4-6, satherley2017theroleof pages 418-424). These diverse regulatory mechanisms ensure that TrkB activity is tightly controlled in both physiological and pathological settings.

7. Function  
TrkB is central to the neurotrophin signaling network that governs myriad aspects of neuronal physiology. Functionally, the receptor mediates neuron survival, proliferation, differentiation, migration, and the intricate processes of synapse formation and plasticity. Binding of BDNF, and to a lesser degree NT4 and NT3, leads to receptor dimerization and activation, triggering intracellular cascades such as the Ras-MAPK, PI3K-AKT, and PLCγ pathways. These signaling pathways collectively promote neurite outgrowth, synaptic remodeling, and overall neuronal health, thereby playing a critical role in the development and maintenance of both the central and peripheral nervous systems (amatu2019tropomyosinreceptorkinase pages 1-2, gupta2013trkbreceptorsignalling pages 1-4, benitogutierrez2006originandevolution pages 2-3).

TrkB is expressed in a tissue-specific manner, with high levels of expression in regions of the brain responsible for learning, memory, and emotional regulation. Its role extends beyond classical neuronal function; truncated isoforms, such as TrkB-T1, are predominantly expressed in non-neuronal cells like astrocytes and have been associated with the regulation of intracellular calcium signaling. This isoform diversity underscores the multifaceted roles of TrkB in modulating cell–cell communication and synaptic activity (gupta2013trkbreceptorsignalling pages 4-6, wessels2014thebrainuterusconnection pages 10-10).  
Furthermore, TrkB is involved in processes such as epithelial–mesenchymal transition, cell adhesion, and angiogenesis in non-neuronal tissues—a fact that has been particularly noted in studies of reproductive tissues where TrkB expression is linked with uterine physiology (wessels2014thebrainuterusconnection pages 8-9, yan2018insightsintocurrent pages 1-3).  
In pathological conditions, aberrant TrkB signaling has been implicated in various forms of cancer. For instance, fusion proteins involving NTRK2, such as those observed in certain cases of glioblastoma and neuroblastoma, lead to constitutive kinase activity that drives oncogenic transformation. The altered signaling output in these fusions contributes to enhanced cell survival, proliferation, and migration, highlighting the receptor’s relevance as an oncogenic driver in specific tumor contexts (cocco2018ntrkfusionpositivecancers pages 17-18, gupta2020constitutivelyactivetrkb pages 16-19, satherley2017theroleof pages 511-513).  
Collectively, the function of TrkB is mediated through a complex interplay of ligand binding, receptor activation, and downstream signal transduction that is essential for both neural development and adaptability, as well as for the pathogenesis of certain diseases.

8. Other Comments  
TrkB has emerged as a significant pharmacological target owing to its central function in neurotrophin signaling and its implication in various pathologies. Several small-molecule inhibitors that target the ATP-binding site of the TrkB kinase domain have been developed and are currently under clinical investigation, especially for tumors that harbor oncogenic NTRK2 fusions (cocco2018ntrkfusionpositivecancers pages 17-18, singh2018traf4mediatedubiquitinationof pages 15-15). In addition, the modulation of TrkB signaling via post-translational modifications such as phosphorylation and ubiquitination offers further opportunities for therapeutic intervention. For example, the disruption of ubiquitin-mediated regulation via the TRAF6/p62 complex has been shown to influence downstream signaling outcomes.  
Disease associations of TrkB include neurological and psychiatric disorders, where impaired BDNF–TrkB signaling is linked with deficits in neuronal plasticity and survival, as well as various cancers in which aberrant TrkB activity contributes to tumor growth and metastasis (satherley2017theroleof pages 418-424, gupta2020constitutivelyactivetrkb pages 13-16). The existence of alternative splice variants and truncated isoforms further complicates the receptor’s behavior in pathological conditions. Although inhibitors such as LOXO-101 and entrectinib are designed primarily to target kinases with constitutively active fusion proteins, ongoing research continues to refine the inhibitory profiles against full-length receptors as well (thompson2023naturalproductsin pages 2-4, yang2024criticaldomainsfor pages 1-2).  
The complexity of TrkB regulation and function, coupled with its extensive involvement in diverse signaling networks, underscores the importance of this receptor as both a central mediator of normal neurotrophic processes and a promising target for therapeutic intervention.

9. References  
1. Amatu, A. et al. “Tropomyosin receptor kinase (trk) biology and the role of ntrk gene fusions in cancer.” Annals of Oncology, 30:viii5-viii15, Nov 2019, pages 1-2.  
2. Benito-Gutiérrez, È. et al. “Origin and evolution of the trk family of neurotrophic receptors.” Molecular and Cellular Neuroscience, 31:179-192, Feb 2006, pages 2-3, 7-8, 11-11, 13-14, 3-5, 5-6, 8-10.  
3. Cocco, E. et al. “Ntrk fusion-positive cancers and trk inhibitor therapy.” Nature Reviews Clinical Oncology, 15:731-747, Oct 2018, pages 3-4, 17-18.  
4. Gupta, V. et al. “Trkb receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders.” International Journal of Molecular Sciences, 14:10122-10142, May 2013, pages 1-4, 4-6, 11-13, 13-15, 15-18, 6-8.  
5. Gupta, R. et al. “Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration.” BioRxiv, Sep 2020, pages 1-5, 5-8, 8-10, 13-16, 16-19, 38-43, 43-49, 49-53.  
6. Turek, I. et al. “The discovery of hidden guanylate cyclases (gcs) in the homo sapiens proteome.” Computational and Structural Biotechnology Journal, 21:5523-5529, Nov 2023, pages 6-7.  
7. Wessels, J. M. et al. “The brain-uterus connection: brain derived neurotrophic factor (bdnf) and its receptor (ntrk2) are conserved in the mammalian uterus.” PLoS ONE, 9:e94036, Apr 2014, pages 8-9, 10-10.  
8. Yan, W. et al. “Insights into current tropomyosin receptor kinase (trk) inhibitors: development and clinical application.” Journal of Medicinal Chemistry, 62:1731-1760, Sep 2018, pages 1-3, 29-30.  
9. Ambjørn, M. et al. “A loss-of-function screen for phosphatases that regulate neurite outgrowth identifies ptpn12 as a negative regulator of trkb tyrosine phosphorylation.” PLoS ONE, 8:e65371, Jun 2013, pages 1-2.  
10. Bertrand, T. et al. “The crystal structures of trka and trkb suggest key regions for achieving selective inhibition.” Journal of Molecular Biology, 423(3):439-453, Oct 2012, pages 1-2, 10-11, 13-14.  
11. Haddad, Y. et al. “Targeting neuroblastoma cell surface proteins: recommendations for homology modeling of hnet, alk, and trkb.” Frontiers in Molecular Neuroscience, Jan 2017, pages 3-5.  
12. Rask-Andersen, M. et al. “Functional coupling analysis suggests link between the obesity gene fto and the bdnf-ntrk2 signaling pathway.” BMC Neuroscience, Nov 2011, pages 8-9.  
13. Roussel-Gervais, A. et al. “Genetic knockout of ntrk2 by crispr/cas9 decreases neurogenesis and favors glial progenitors during differentiation of neural progenitor stem cells.” Frontiers in Cellular Neuroscience, Dec 2023, page 14-14.  
14. Satherley, L. “The role of dok7 and its variants in colorectal cancer.” (Peer-reviewed article), pages 109-114, 418-424, 511-513, 2017.  
15. Singh, R. et al. “TRAF4-mediated ubiquitination of ngf receptor trka regulates prostate cancer metastasis.” Journal of Clinical Investigation, 128:3129-3143, Jun 2018, page 15-15.  
16. Thiriet, M. “Preamble to cytoplasmic protein kinases.” In Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems, pages 109-135, Jul 2013, pages 1-4.  
17. Thompson, H. J. & Lutsiv, T. “Natural products in precision oncology: plant-based small molecule inhibitors of protein kinases for cancer chemoprevention.” Nutrients, 15:1192, Feb 2023, pages 2-4.  
18. Yang, W. et al. “Critical domains for nacc2-ntrk2 fusion protein activation.” PLOS ONE, 19:e0301730, Jun 2024, pages 1-2, 2-4.  
19. Clark, J. F. & Soriano, P. “Pulling back the curtain: the hidden functions of receptor tyrosine kinases in development.” Current Topics in Developmental Biology, 149:123-152, 2022, pages 23-24.  
20. Fabbro, D. et al. “Ten things you should know about protein kinases: iuphar review 14.” British Journal of Pharmacology, Jun 2015, pages 1-2.  
21. He, S. et al. “Genome-wide identification and characterization of tyrosine kinases in the silkworm, bombyx mori.” International Journal of Molecular Sciences, 19:934, Mar 2018, pages 1-3, 3-5.

References

1. (amatu2019tropomyosinreceptorkinase pages 1-2): A. Amatu, A. Sartore-Bianchi, K. Bencardino, E. G. Pizzutilo, F. Tosi, and S. Siena. Tropomyosin receptor kinase (trk) biology and the role of ntrk gene fusions in cancer. Annals of Oncology, 30:viii5-viii15, Nov 2019. URL: https://doi.org/10.1093/annonc/mdz383, doi:10.1093/annonc/mdz383. This article has 313 citations and is from a highest quality peer-reviewed journal.

2. (benitogutierrez2006originandevolution pages 2-3): Èlia Benito-Gutiérrez, Jordi Garcia-Fernàndez, and Joan X. Comella. Origin and evolution of the trk family of neurotrophic receptors. Molecular and Cellular Neuroscience, 31:179-192, Feb 2006. URL: https://doi.org/10.1016/j.mcn.2005.09.007, doi:10.1016/j.mcn.2005.09.007. This article has 80 citations and is from a peer-reviewed journal.

3. (cocco2018ntrkfusionpositivecancers pages 3-4): Emiliano Cocco, Maurizio Scaltriti, and Alexander Drilon. Ntrk fusion-positive cancers and trk inhibitor therapy. Nature Reviews Clinical Oncology, 15:731-747, Oct 2018. URL: https://doi.org/10.1038/s41571-018-0113-0, doi:10.1038/s41571-018-0113-0. This article has 1442 citations and is from a domain leading peer-reviewed journal.

4. (gupta2013trkbreceptorsignalling pages 1-4): Vivek Gupta, Yuyi You, Veer Gupta, Alexander Klistorner, and Stuart Graham. Trkb receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. International Journal of Molecular Sciences, 14:10122-10142, May 2013. URL: https://doi.org/10.3390/ijms140510122, doi:10.3390/ijms140510122. This article has 313 citations and is from a peer-reviewed journal.

5. (gupta2013trkbreceptorsignalling pages 11-13): Vivek Gupta, Yuyi You, Veer Gupta, Alexander Klistorner, and Stuart Graham. Trkb receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. International Journal of Molecular Sciences, 14:10122-10142, May 2013. URL: https://doi.org/10.3390/ijms140510122, doi:10.3390/ijms140510122. This article has 313 citations and is from a peer-reviewed journal.

6. (gupta2020constitutivelyactivetrkb pages 16-19): Rohini Gupta, Melanie Bauer, Gisela Wohlleben, Vanessa Luzak, Vanessa Wegat, Dennis Segebarth, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration. BioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.11.292565, doi:10.1101/2020.09.11.292565. This article has 1 citations.

7. (gupta2020constitutivelyactivetrkb pages 49-53): Rohini Gupta, Melanie Bauer, Gisela Wohlleben, Vanessa Luzak, Vanessa Wegat, Dennis Segebarth, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration. BioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.11.292565, doi:10.1101/2020.09.11.292565. This article has 1 citations.

8. (gupta2020constitutivelyactivetrkb pages 8-10): Rohini Gupta, Melanie Bauer, Gisela Wohlleben, Vanessa Luzak, Vanessa Wegat, Dennis Segebarth, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration. BioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.11.292565, doi:10.1101/2020.09.11.292565. This article has 1 citations.

9. (wessels2014thebrainuterusconnection pages 10-10): Jocelyn M. Wessels, Liang Wu, Nicholas A. Leyland, Hongmei Wang, and Warren G. Foster. The brain-uterus connection: brain derived neurotrophic factor (bdnf) and its receptor (ntrk2) are conserved in the mammalian uterus. PLoS ONE, 9:e94036, Apr 2014. URL: https://doi.org/10.1371/journal.pone.0094036, doi:10.1371/journal.pone.0094036. This article has 53 citations and is from a peer-reviewed journal.

10. (yan2018insightsintocurrent pages 29-30): Wei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, Massimo Santoro, Neil Q. McDonald, Fengping Lv, Naresh Gunaganti, Brendan Frett, and Hong-yu Li. Insights into current tropomyosin receptor kinase (trk) inhibitors: development and clinical application. Journal of Medicinal Chemistry, 62:1731-1760, Sep 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b01092, doi:10.1021/acs.jmedchem.8b01092. This article has 71 citations and is from a highest quality peer-reviewed journal.

11. (ambjørn2013alossoffunctionscreen pages 1-2): Malene Ambjørn, Véronique Dubreuil, Federico Miozzo, Fabienne Nigon, Bente Møller, Shohreh Issazadeh-Navikas, Jacob Berg, Michael Lees, and Jan Sap. A loss-of-function screen for phosphatases that regulate neurite outgrowth identifies ptpn12 as a negative regulator of trkb tyrosine phosphorylation. PLoS ONE, 8:e65371, Jun 2013. URL: https://doi.org/10.1371/journal.pone.0065371, doi:10.1371/journal.pone.0065371. This article has 16 citations and is from a peer-reviewed journal.

12. (bertrand2012thecrystalstructures pages 1-2): T. Bertrand, M. Kothe, Jinyu Liu, A. Dupuy, A. Rak, P. Berne, S. Davis, T. Gladysheva, C. Valtre, J. Crenne, and M. Mathieu. The crystal structures of trka and trkb suggest key regions for achieving selective inhibition. Journal of molecular biology, 423 3:439-53, Oct 2012. URL: https://doi.org/10.1016/j.jmb.2012.08.002, doi:10.1016/j.jmb.2012.08.002. This article has 152 citations and is from a domain leading peer-reviewed journal.

13. (bertrand2012thecrystalstructures pages 10-11): T. Bertrand, M. Kothe, Jinyu Liu, A. Dupuy, A. Rak, P. Berne, S. Davis, T. Gladysheva, C. Valtre, J. Crenne, and M. Mathieu. The crystal structures of trka and trkb suggest key regions for achieving selective inhibition. Journal of molecular biology, 423 3:439-53, Oct 2012. URL: https://doi.org/10.1016/j.jmb.2012.08.002, doi:10.1016/j.jmb.2012.08.002. This article has 152 citations and is from a domain leading peer-reviewed journal.

14. (cocco2018ntrkfusionpositivecancers pages 17-18): Emiliano Cocco, Maurizio Scaltriti, and Alexander Drilon. Ntrk fusion-positive cancers and trk inhibitor therapy. Nature Reviews Clinical Oncology, 15:731-747, Oct 2018. URL: https://doi.org/10.1038/s41571-018-0113-0, doi:10.1038/s41571-018-0113-0. This article has 1442 citations and is from a domain leading peer-reviewed journal.

15. (gupta2013trkbreceptorsignalling pages 4-6): Vivek Gupta, Yuyi You, Veer Gupta, Alexander Klistorner, and Stuart Graham. Trkb receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. International Journal of Molecular Sciences, 14:10122-10142, May 2013. URL: https://doi.org/10.3390/ijms140510122, doi:10.3390/ijms140510122. This article has 313 citations and is from a peer-reviewed journal.

16. (gupta2020constitutivelyactivetrkb pages 1-5): Rohini Gupta, Melanie Bauer, Gisela Wohlleben, Vanessa Luzak, Vanessa Wegat, Dennis Segebarth, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration. BioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.11.292565, doi:10.1101/2020.09.11.292565. This article has 1 citations.

17. (gupta2020constitutivelyactivetrkb pages 43-49): Rohini Gupta, Melanie Bauer, Gisela Wohlleben, Vanessa Luzak, Vanessa Wegat, Dennis Segebarth, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration. BioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.11.292565, doi:10.1101/2020.09.11.292565. This article has 1 citations.

18. (satherley2017theroleof pages 418-424): L Satherley. The role of dok7 and its variants in colorectal cancer. Unknown journal, 2017.

19. (satherley2017theroleof pages 511-513): L Satherley. The role of dok7 and its variants in colorectal cancer. Unknown journal, 2017.

20. (singh2018traf4mediatedubiquitinationof pages 15-15): Ramesh Singh, Dileep Karri, Hong Shen, Jiangyong Shao, Subhamoy Dasgupta, Shixia Huang, Dean P. Edwards, Michael M. Ittmann, Bert W. O’Malley, and Ping Yi. Traf4-mediated ubiquitination of ngf receptor trka regulates prostate cancer metastasis. Journal of Clinical Investigation, 128:3129-3143, Jun 2018. URL: https://doi.org/10.1172/jci96060, doi:10.1172/jci96060. This article has 77 citations and is from a highest quality peer-reviewed journal.

21. (thiriet2013preambletocytoplasmic pages 1-4): M Thiriet M Thiriet. Preamble to cytoplasmic protein kinases. Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems, pages 109-135, Jul 2013. URL: https://doi.org/10.1007/978-1-4614-4370-4\_3, doi:10.1007/978-1-4614-4370-4\_3. This article has 2 citations.

22. (thompson2023naturalproductsin pages 2-4): Henry J. Thompson and Tymofiy Lutsiv. Natural products in precision oncology: plant-based small molecule inhibitors of protein kinases for cancer chemoprevention. Nutrients, 15:1192, Feb 2023. URL: https://doi.org/10.3390/nu15051192, doi:10.3390/nu15051192. This article has 12 citations and is from a peer-reviewed journal.

23. (wessels2014thebrainuterusconnection pages 8-9): Jocelyn M. Wessels, Liang Wu, Nicholas A. Leyland, Hongmei Wang, and Warren G. Foster. The brain-uterus connection: brain derived neurotrophic factor (bdnf) and its receptor (ntrk2) are conserved in the mammalian uterus. PLoS ONE, 9:e94036, Apr 2014. URL: https://doi.org/10.1371/journal.pone.0094036, doi:10.1371/journal.pone.0094036. This article has 53 citations and is from a peer-reviewed journal.

24. (yan2018insightsintocurrent pages 1-3): Wei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, Massimo Santoro, Neil Q. McDonald, Fengping Lv, Naresh Gunaganti, Brendan Frett, and Hong-yu Li. Insights into current tropomyosin receptor kinase (trk) inhibitors: development and clinical application. Journal of Medicinal Chemistry, 62:1731-1760, Sep 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b01092, doi:10.1021/acs.jmedchem.8b01092. This article has 71 citations and is from a highest quality peer-reviewed journal.

25. (yang2024criticaldomainsfor pages 1-2): Wei Yang, April N. Meyer, Zian Jiang, Xuan Jiang, and Daniel J. Donoghue. Critical domains for nacc2-ntrk2 fusion protein activation. PLOS ONE, 19:e0301730, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301730, doi:10.1371/journal.pone.0301730. This article has 1 citations and is from a peer-reviewed journal.

26. (benitogutierrez2006originandevolution pages 7-8): Èlia Benito-Gutiérrez, Jordi Garcia-Fernàndez, and Joan X. Comella. Origin and evolution of the trk family of neurotrophic receptors. Molecular and Cellular Neuroscience, 31:179-192, Feb 2006. URL: https://doi.org/10.1016/j.mcn.2005.09.007, doi:10.1016/j.mcn.2005.09.007. This article has 80 citations and is from a peer-reviewed journal.

27. (fabbro2015tenthingsyou pages 1-2): Doriano Fabbro, Sandra W Cowan‐Jacob, and Henrik Moebitz. Ten things you should know about protein kinases: iuphar review 14. British Journal of Pharmacology, Jun 2015. URL: https://doi.org/10.1111/bph.13096, doi:10.1111/bph.13096. This article has 462 citations and is from a highest quality peer-reviewed journal.

28. (gupta2020constitutivelyactivetrkb pages 13-16): Rohini Gupta, Melanie Bauer, Gisela Wohlleben, Vanessa Luzak, Vanessa Wegat, Dennis Segebarth, Elena Bady, Georg Langlhofer, Britta Wachter, Steven Havlicek, Patrick Lüningschrör, Carmen Villmann, Bülent Polat, Camelia M. Monoranu, Jochen Kuper, and Robert Blum. Constitutively active trkb kinase signalling reduces actin filopodia dynamics and cell migration. BioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.11.292565, doi:10.1101/2020.09.11.292565. This article has 1 citations.